Cargando…

Neuropsychiatric Disorders and COVID-19: What We Know So Far

SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) affects the central nervous system (CNS), which is shown in a significant number of patients with neurological events. In this study, an updated literature review was carried out regarding neurological disorders in COVID-19. Neurological s...

Descripción completa

Detalles Bibliográficos
Autores principales: Majolo, Fernanda, da Silva, Guilherme Liberato, Vieira, Lucas, Anli, Cetin, Timmers, Luís Fernando Saraiva Macedo, Laufer, Stefan, Goettert, Márcia Inês
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465079/
https://www.ncbi.nlm.nih.gov/pubmed/34577633
http://dx.doi.org/10.3390/ph14090933
_version_ 1784572779642748928
author Majolo, Fernanda
da Silva, Guilherme Liberato
Vieira, Lucas
Anli, Cetin
Timmers, Luís Fernando Saraiva Macedo
Laufer, Stefan
Goettert, Márcia Inês
author_facet Majolo, Fernanda
da Silva, Guilherme Liberato
Vieira, Lucas
Anli, Cetin
Timmers, Luís Fernando Saraiva Macedo
Laufer, Stefan
Goettert, Márcia Inês
author_sort Majolo, Fernanda
collection PubMed
description SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) affects the central nervous system (CNS), which is shown in a significant number of patients with neurological events. In this study, an updated literature review was carried out regarding neurological disorders in COVID-19. Neurological symptoms are more common in patients with severe infection according to their respiratory status and divided into three categories: (1) CNS manifestations; (2) cranial and peripheral nervous system manifestations; and (3) skeletal muscle injury manifestations. Patients with pre-existing cerebrovascular disease are at a higher risk of admission to the intensive care unit (ICU) and mortality. The neurological manifestations associated with COVID-19 are of great importance, but when life-threatening abnormal vital signs occur in severely ill COVID-19 patients, neurological problems are usually not considered. It is crucial to search for new treatments for brain damage, as well as for alternative therapies that recover the damaged brain and reduce the inflammatory response and its consequences for other organs. In addition, there is a need to diagnose these manifestations as early as possible to limit long-term consequences. Therefore, much research is needed to explain the involvement of SARS-CoV-2 causing these neurological symptoms because scientists know zero about it.
format Online
Article
Text
id pubmed-8465079
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84650792021-09-27 Neuropsychiatric Disorders and COVID-19: What We Know So Far Majolo, Fernanda da Silva, Guilherme Liberato Vieira, Lucas Anli, Cetin Timmers, Luís Fernando Saraiva Macedo Laufer, Stefan Goettert, Márcia Inês Pharmaceuticals (Basel) Review SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus-2) affects the central nervous system (CNS), which is shown in a significant number of patients with neurological events. In this study, an updated literature review was carried out regarding neurological disorders in COVID-19. Neurological symptoms are more common in patients with severe infection according to their respiratory status and divided into three categories: (1) CNS manifestations; (2) cranial and peripheral nervous system manifestations; and (3) skeletal muscle injury manifestations. Patients with pre-existing cerebrovascular disease are at a higher risk of admission to the intensive care unit (ICU) and mortality. The neurological manifestations associated with COVID-19 are of great importance, but when life-threatening abnormal vital signs occur in severely ill COVID-19 patients, neurological problems are usually not considered. It is crucial to search for new treatments for brain damage, as well as for alternative therapies that recover the damaged brain and reduce the inflammatory response and its consequences for other organs. In addition, there is a need to diagnose these manifestations as early as possible to limit long-term consequences. Therefore, much research is needed to explain the involvement of SARS-CoV-2 causing these neurological symptoms because scientists know zero about it. MDPI 2021-09-17 /pmc/articles/PMC8465079/ /pubmed/34577633 http://dx.doi.org/10.3390/ph14090933 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Majolo, Fernanda
da Silva, Guilherme Liberato
Vieira, Lucas
Anli, Cetin
Timmers, Luís Fernando Saraiva Macedo
Laufer, Stefan
Goettert, Márcia Inês
Neuropsychiatric Disorders and COVID-19: What We Know So Far
title Neuropsychiatric Disorders and COVID-19: What We Know So Far
title_full Neuropsychiatric Disorders and COVID-19: What We Know So Far
title_fullStr Neuropsychiatric Disorders and COVID-19: What We Know So Far
title_full_unstemmed Neuropsychiatric Disorders and COVID-19: What We Know So Far
title_short Neuropsychiatric Disorders and COVID-19: What We Know So Far
title_sort neuropsychiatric disorders and covid-19: what we know so far
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465079/
https://www.ncbi.nlm.nih.gov/pubmed/34577633
http://dx.doi.org/10.3390/ph14090933
work_keys_str_mv AT majolofernanda neuropsychiatricdisordersandcovid19whatweknowsofar
AT dasilvaguilhermeliberato neuropsychiatricdisordersandcovid19whatweknowsofar
AT vieiralucas neuropsychiatricdisordersandcovid19whatweknowsofar
AT anlicetin neuropsychiatricdisordersandcovid19whatweknowsofar
AT timmersluisfernandosaraivamacedo neuropsychiatricdisordersandcovid19whatweknowsofar
AT lauferstefan neuropsychiatricdisordersandcovid19whatweknowsofar
AT goettertmarciaines neuropsychiatricdisordersandcovid19whatweknowsofar